Blarcamesine Shows Promise in Alzheimer’s Treatment: Anavex Life Sciences Reports
In a breakthrough for Alzheimer’s disease research, Anavex Life Sciences has announced promising results from their phase 2b/3 clinical trial of blarcamesine (ANAVEX®2-73). This investigational drug has shown significant efficacy in reducing amyloid-ß biomarkers and slowing brain atrophy in patients with early-stage Alzheimer’s. According to Anavex Life Sciences, the study, which involved 508 participants across […]